Divya R Chaudhary

US Patent:

7584087, Sep 1, 2009

Filed:

Apr 6, 2005

Appl. No.:

11/099958

Inventors:

Zhang Bao Xu - Tewksbury MA, US
Stephane Olland - Arlington MA, US
Scott Wolfrom - Somerville MA, US
Karl Malakian - Boxborough MA, US
Laura Lin - Weston MA, US
Mark Stahl - Lexington MA, US
Julie Lee - Somerville MA, US
Lori Fitz - Somerville MA, US
Rita Greco - Charlestown MA, US
Divya Chaudhary - Andover MA, US
William Stuart Somers - Lexington MA, US
Lidia Mosyak - Newton MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

G06G 7/58
G01N 31/00
G01N 33/573
G01N 33/53
C12Q 1/00
C12Q 1/48
C12N 9/99
C12N 9/12

US Classification:

703 11, 702 27, 435 4, 435 74, 435 771, 435 15, 435184, 435194

Abstract:

A three-dimensional structure of human protein kinase C theta (PKCθ) can be used in methods of designing an agent that interacts with PKCθ. The agent can be an inhibitor of PKCθ activity.

US Patent:

7700301, Apr 20, 2010

Filed:

Sep 11, 2006

Appl. No.:

11/519186

Inventors:

Clive R. Wood - Boston MA, US
Gordon J. Freeman - Brookline MA, US
Divya Chaudhary - Andover MA, US

Assignee:

Dana-Farber Cancer Institute Inc. - Boston MA
Wyeth - Madison NJ

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

Disclosed are screening assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule.

US Patent:

20020068696, Jun 6, 2002

Filed:

Feb 9, 2001

Appl. No.:

09/780532

Inventors:

Clive Wood - Boston MA, US
Divya Chaudhary - Andover MA, US
Andrew Long - Chelmsford MA, US

International Classification:

A61K038/16
A61K048/00

US Classification:

514/012000, 514/044000

Abstract:

The present invention relates, at least in part, to methods of modulating proliferation and apoptotic state of cells using agents that modulate the expression and/or activity of TRADE family polypeptides. In addition, the invention provides two novel members of the TRADE family of molecules.

US Patent:

20030044768, Mar 6, 2003

Filed:

Apr 2, 2002

Appl. No.:

10/115615

Inventors:

Clive Wood - Boston MA, US
Gordon Freeman - Brookline MA, US
Divya Chaudhary - Andover MA, US

Assignee:

Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q001/00
G01N033/53
G01N033/567

US Classification:

435/004000, 435/007200

Abstract:

Disclosed is a method for modulating an immune response by modulating signaling via PD-1. The immune response may be downregulated by increasing signaling via PD-1, or may be upregulated by decreasing signaling via PD-1. Agents which are useful for stimulating signaling via PD-1 to downregulate an immune response include an activating antibody that recognizes PD-1, a form of B7-4 that binds to an inhibitory receptor, and a small molecule that binds to PD-1. Agents which are useful for inhibiting signaling via PD-1 to upregulate an immune response include a blocking antibody that recognizes PD-1, a non-activating form of B7-4, an antibody that recognizes B7-4, and a soluble form of PD-1. Also disclosed is a method for modulating the interaction of B7-4 with an inhibitory receptor on an immune cell. The method comprises contacting an antigen presenting cell which expresses B7-4 with an agent such as a form of B7-4, a form of PD-1, or an agent that modulates the interaction of B7-4 and PD-1. Also disclosed is a method for inhibiting activation of an immune cell via a non-apoptotic mechanism by increasing the activity or expression of PD-1 in the immune cell. The disclosed methods for modulating an immune response are useful, for instance as therapeutic treatment of a subject with conditions that would benefit from immune response modulation. For instance, a condition such as a tumor, a neurological disease, or an immunosuppressive disease, would be treated by upregulating an immune response, and conditions such as a transplant, an allergy, or an autoimmune disorder would benefit from downregulation of an immune response. Assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule are also disclosed. Further disclosed are a vaccine and also other compositions which contain agents that modulate signaling via PD-1.

US Patent:

20050164323, Jul 28, 2005

Filed:

Dec 22, 2004

Appl. No.:

11/022327

Inventors:

Divya Chaudhary - Andover MA, US
Marion Kasaian - Charlestown MA, US
Cara Williams - Methuen MA, US
Suzana Marusic - Reading MA, US
Robert Czerwinski - North Grafton MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12Q001/68
A61K038/00
C12N005/08
C12Q001/48

US Classification:

435015000, 514002000, 435372000

Abstract:

Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the production of a PKC-θ protein, as well as for agents that inhibit the kinase activity of a PKC-θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC-θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-θ protein or the kinase activity of a PKC-θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-θ is also disclosed.

US Patent:

20090325176, Dec 31, 2009

Filed:

Jun 5, 2009

Appl. No.:

12/478940

Inventors:

Margot Mary O'Toole - Newton MA, US
Frederick William Immermann - Suffern NY, US
Padmalatha Sunkara Reddy - Lexington MA, US
Andrew Arthur Hill - Cambridge MA, US
John Louis Ryan - Philadelphia PA, US
Andrew Joseph Dorner - Lexington MA, US
Cristina Ileana Csimma - Lincoln MA, US
Charlotte Marie McKee - Newton MA, US
Wei Liu - Lexington MA, US
Divya Chaudhary - Andover MA, US
Matthew Ren Silver - Rockport MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

C12Q 1/68
G01N 33/53
C40B 40/08
C40B 40/10

US Classification:

435 6, 435 71, 506 17, 506 18

Abstract:

The present invention provides methods for the assessment, diagnosis, or prognosis of asthma exacerbation, by assessing the level of expression of asthma exacerbation gene products in a sample derived from a patient. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma.

US Patent:

20110033884, Feb 10, 2011

Filed:

Apr 16, 2010

Appl. No.:

12/761704

Inventors:

Clive Wood - Boston MA, US
Gordon J. Freeman - Brookline MA, US
Divya Chaudhary - Andover MA, US

International Classification:

C12Q 1/02

US Classification:

435 29

Abstract:

Disclosed is a method for modulating an immune response by modulating signaling via PD-1. The immune response may be downregulated by increasing signaling via PD-1, or may be upregulated by decreasing signaling via PD-1. Agents which are useful for stimulating signaling via PD-1 to downregulate an immune response include an activating antibody that recognizes PD-1, a form of B7-4 that binds to an inhibitory receptor, and a small molecule that binds to PD-1. Agents which are useful for inhibiting signaling via PD-1 to upregulate an immune response include a blocking antibody that recognizes PD-1, a non-activating form of B7-4, an antibody that recognizes B7-4, and a soluble form of PD-1. Also disclosed is a method for modulating the interaction of B7-4 with an inhibitory receptor on an immune cell. The method comprises contacting an antigen presenting cell which expresses B7-4 with an agent such as a form of B7-4, a form of PD-1, or an agent that modulates the interaction of B7-4 and PD-1. Also disclosed is a method for inhibiting activation of an immune cell via a non-apoptotic mechanism by increasing the activity or expression of PD-1 in the immune cell. The disclosed methods for modulating an immune response are useful, for instance as therapeutic treatment of a subject with conditions that would benefit from immune response modulation. For instance, a condition such as a tumor, a neurological disease, or an immunosuppressive disease, would be treated by upregulating an immune response, and conditions such as a transplant, an allergy, or an autoimmune disorder would benefit from downregulation of an immune response. Assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule are also disclosed. Further disclosed are a vaccine and also other compositions which contain agents that modulate signaling via PD-1.